Q-omics provides the consensus-scored ATRIP profile across patient tissues and cancer cell-line models. ATRIP expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ATRIP is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, ATRIP RNA expression shows 19,169 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, BLCA, and LSCC as cancer lineages where ATRIP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATRIP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATRIP survival associations across molecular data types. ATRIP RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATRIP RNA expression–survival associations across cancer types. High ATRIP expression shows unfavorable associations in LIHC, KIRC and KICH, but favorable associations in UCS, SCLC and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ATRIP RNA expression.
This table summarizes ATRIP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ATRIP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATRIP shows lower tumor expression in KIRC and higher tumor expression in BLCA, COAD, LIHC, STAD and LUSC. The BLCA box plot shows higher ATRIP RNA expression in tumor versus normal tissue (log2 FC = +0.133, t-test p < 0.001).
This table shows molecular features associated with ATRIP in patient tissues and cancer cell lines. In patient samples, ATRIP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATRIP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
